November 18, 2026
Health news, explained with evidence
LIVE
Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine

Combining Prostatic Lift and Radiotherapy Appears Safe for Prostate Cancer Patients With BPH

❤️ Conditions & Care 2 min read 👁 5

A phase I clinical trial suggests that using a prostatic urethral lift implant alongside stereotactic ablative body radiotherapy is a safe and feasible option for men dealing with both prostate cancer and benign prostatic hyperplasia.

Combining Prostatic Lift and Radiotherapy Appears Safe for Prostate Cancer Patients With BPH❤️Conditions & Care

Photo: Nature Health Sciences

Key points

  • Phase I clinical trial evaluated 15 patients with intermediate-risk prostate cancer and symptomatic BPH.
  • Combined prostatic urethral lift (PUL) and stereotactic ablative body radiotherapy showed no severe (grade 3+) toxicities.
  • Patients demonstrated significant improvements in urinary symptom scores at three months post-radiation.

Researchers evaluating a novel treatment strategy have found that combining a prostatic urethral lift (PUL) with stereotactic ablative body radiotherapy (SAbR) appears safe and feasible for men diagnosed with intermediate-risk prostate cancer and concurrent benign prostatic hyperplasia (BPH). Traditionally, patients with severe lower urinary tract symptoms from BPH are often ruled out for SAbR due to the heightened risk of worsening urinary complications from high-dose radiation.

The single-arm phase I trial enrolled 15 participants who underwent a single general anesthesia procedure to receive the PUL implant, rectoprostatic spacer gel, and fiducial markers, followed by SAbR treatment. Investigators reported that four individuals experienced mild, grade 1-2 perioperative complications related to the PUL implantation, while eight patients experienced mild genitourinary adverse events during or after radiation. No severe toxicities of grade 3 or higher were observed among the group.

Furthermore, participants showed statistically significant improvements in urinary function following the intervention. The mean American Urological Association Symptom Score dropped from 22.1 down to 14.0 at three months post-radiation, and obstructive scores similarly improved. Experts note that while these findings are encouraging, the study was a small, non-blinded early-stage trial with a short three-month follow-up window, meaning larger randomized studies are needed to confirm long-term outcomes.

What to know: The early-stage trial of 15 patients indicates that mechanical retraction via a prostatic urethral lift may help clear men with BPH for SAbR prostate cancer treatment without severe side effects. Readers should always consult a qualified healthcare provider for personalized medical decisions and treatment options.

Source Nature Health Sciences — nature.com/articles/s41391-026-01169-6 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.